International Maternal Pediatric Adolescent AIDS Clinical Trials (IMPAACT)

-
Investigator: Francesca T. Aweeka, PharmD
Sponsor: Social & Scientific Systems, Inc.

Location(s): Malawi; Uganda; United States

Description

The International Maternal Pediatric Adolescent AIDS Clinical Trials Network (IMPAACT) is a cooperative group of institutions, investigators, and other collaborators organized for the purpose of evaluating potential therapies for HIV infection and its sequelae in the infant, pediatric, adolescent and pregnant women populations. IMPAACT has two components; one is funded by the National Institute for Allergy and Infectious Diseases (NIAID), and one by the National Institute of Child Health and Human Development (NICHD).

HIV Treatment Scientific Committee-An increasing number of HIV-infected children, globally, now have access to antiretroviral therapy (ART).  The Primary Therapy Scientific Committee’s (PTSC) agenda aims to optimize antiretroviral management of children from infancy through adolescence and into young adulthood. 

HIV CURE Scientific Committee- Identify ways to block establishment and maintenance of HIV reservoirs that preclude HIV CURE in infected infants, children and adolescents.  

HIV Prevention Scientific Committee- The IMPAACT Prevention of Mother-to-Child Transmission Scientific Committee (PMTCT SC) aims to maximize opportunities for the prevention of mother-to-child HIV-1 transmission including breastfeeding transmission both domestically and internationally.  

HIV/ARV Complications Scientific Committee- Focuses on the global epidemiology, prevention, and management of complications from HIV-1 infection and its treatment. Its agenda includes evaluations of both short and long term drug toxicities, treatment and prevention of opportunistic infections, and the long term consequences of HIV infection.

Hepatitis Scientific Committee -The mission of the Hepatitis Scientific Committee (HSC) is to develop safe and effective therapeutic strategies for the prevention and treatment of viral hepatitis and to define treatment practice guidelines for HIV-co-infected and mono-infected children, adolescents and pregnant women in both resource-rich and resource-poor countries.

Tuberculosis Scientific Committee-Develop studies that address identification, prevention and treatment of maternal child Tuberculosis (TB) worldwide. Priority areas of research include PK, safety and efficacy of new TB drugs and regimens, the evaluation of new TB diagnostics and TB vaccines.

Vaccines Scientific Committee- The Vaccines Scientific Committee (VSC) addresses the development of effective vaccine and immune-based therapy regimens to prevent or modify HIV-1 infection and other infectious diseases in infants, children, and adolescents. In addition, the committee identifies and prioritizes immunology, HIV vaccine, and other vaccine-related pathogenesis questions which are added to Vaccine SC protocols or studies that are developed from other scientific committees.

Women’s Health Advisory Committee- Foster the development of studies that address scientific questions pertaining to HIV infected women including but not limited to assessing optimal antiretroviral therapy (ART) over the course of their lifetime.